Group 1 - The U.S. regulatory agency has approved Moderna's COVID-19 vaccine for children under 12 at high risk, but the scope of eligibility has been narrowed compared to previous guidelines [1] - Under Robert F. Kennedy Jr.'s leadership, the U.S. health department has implemented measures to limit the use of COVID-19 vaccines for children, contrasting with the previous recommendation for vaccination for all individuals aged 6 months and older [1] - Public health experts express concerns that limiting vaccine access may pose risks to children under 2 years old, who are more susceptible to COVID-19 infection [1] Group 2 - Only 13% of children received the COVID-19 vaccine in the last quarter, which is half the vaccination rate of adults [2] - Over 150 children under 18 have died from COVID-19 in the year leading up to August 2024, indicating a serious risk for children [2] - Approximately 6 million American children may experience long-term effects from COVID-19, including an increased risk of developing type 2 diabetes [2] Group 3 - Moderna's stock price increased by over 3% in early trading [3]

美国食品药品管理局（FDA）要求就新冠疫苗接种出具罕见心脏病风险提示。（美联社） ...

Anavex Life Sciences则收跌9.95%表现倒数第三，Prime Medicine跌15.01%，Alumis跌16.89%。 | NASDAQ Biotechnology | 4.177.9 +63.9 (+1.55%) | 4 | * | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | B | 名称 ▼ | 磨製 ~ | 交易量 ~ | 普遍。 | 磨低~ | 涨跌幅 ▼ | 看涨 P | 时间 ~ | | | | F | 47.57 | 图图 品 | 03:28:29 0 | Akero Therapeutics | 49.05 | 37.89 | +24.72% | 6.77M | MI | | | D | 图 品 合 | 03:59:28 0 | 2.09 | +24.40% | 10.2M | Sana Biotechnology | 2.10 | 1.63 | MI | | | F | 03:59:29 0 | 9.03 | 9.34 | 图 品 | +17.2 ...

美国食品药品管理局（FDA）授权对健康的儿童和成年人展开接种新冠疫苗加强针的（临床）试验。 ...

美国食品药品监督管理局（FDA）仍然批准为老年人和患病人群提供更新版的新冠疫苗加强针。 ...